The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.
Identifieur interne : 000092 ( Main/Exploration ); précédent : 000091; suivant : 000093The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.
Auteurs : Kenneth Maiese [États-Unis]Source :
- Current neurovascular research [ 1875-5739 ] ; 2020.
Abstract
As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19.
DOI: 10.2174/1567202617666200425205122
PubMed: 32334502
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000029
- to stream PubMed, to step Curation: 000029
- to stream PubMed, to step Checkpoint: 000030
- to stream Ncbi, to step Merge: 001033
- to stream Ncbi, to step Curation: 001033
- to stream Ncbi, to step Checkpoint: 001033
- to stream Main, to step Merge: 000092
- to stream Main, to step Curation: 000092
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.</title><author><name sortKey="Maiese, Kenneth" sort="Maiese, Kenneth" uniqKey="Maiese K" first="Kenneth" last="Maiese">Kenneth Maiese</name><affiliation wicri:level="2"><nlm:affiliation>Cellular and Molecular Signaling New York, New York 10022. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cellular and Molecular Signaling New York</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32334502</idno><idno type="pmid">32334502</idno><idno type="doi">10.2174/1567202617666200425205122</idno><idno type="wicri:Area/PubMed/Corpus">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000029</idno><idno type="wicri:Area/PubMed/Curation">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000029</idno><idno type="wicri:Area/PubMed/Checkpoint">000030</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000030</idno><idno type="wicri:Area/Ncbi/Merge">001033</idno><idno type="wicri:Area/Ncbi/Curation">001033</idno><idno type="wicri:Area/Ncbi/Checkpoint">001033</idno><idno type="wicri:Area/Main/Merge">000092</idno><idno type="wicri:Area/Main/Curation">000092</idno><idno type="wicri:Area/Main/Exploration">000092</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.</title><author><name sortKey="Maiese, Kenneth" sort="Maiese, Kenneth" uniqKey="Maiese K" first="Kenneth" last="Maiese">Kenneth Maiese</name><affiliation wicri:level="2"><nlm:affiliation>Cellular and Molecular Signaling New York, New York 10022. United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cellular and Molecular Signaling New York</wicri:cityArea></affiliation></author></analytic><series><title level="j">Current neurovascular research</title><idno type="eISSN">1875-5739</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such avenue that may prove to be exceeding fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation, a significant disability tied to COVID-19. Furthermore, pathways that can activate mTOR may be necessary for antihepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with greater understanding of this novel pathway, new Maiese, CNR 17,3, mTOR and Antivirals, treatments against several viral infections may successfully emerge including therapy directed for SARS-CoV-2 and COVID-19.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Maiese, Kenneth" sort="Maiese, Kenneth" uniqKey="Maiese K" first="Kenneth" last="Maiese">Kenneth Maiese</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32334502
|texte= The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32334502" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |